Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for Part 1 of the New Drug Application for dasiglucagon for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age and older with congenital hyperinsulinism for up to 3 weeks of dosing.
